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Abstract 
Introduction: Low molecular weight heparins (LMWHs) are used worldwide for the 
treatment and prophylaxis of thromboembolic disorders. Routine laboratory tests are not 
required due to the predictable pharmacokinetics of LMWHs, with the exception of pregnant 
patients, children, patients with renal failure, morbid obesity, or advanced age. Anti-Factor 
Xa (anti-FXa) plasma levels are most often employed in the assessment and guidance of 
accurate dosing in these patient cohorts.  
Materials and methods: A LMWH calibration curve was generated using citrated human 
pooled plasma spiked with pharmacologically relevant concentrations (0–1 U/ml) of two low 
molecular weight heparins; enoxaparin and tinzaparin. Least squares analysis determined the 
best curve fit for this set of data which returned low sum of squares (SS) values for the log 
linear fit with an R
2
 value of 0.995. Patient sample concentrations for the fluorogenic anti-
FXa assay were determined using the log linear regression equation and correlated with the 
values reported by the hospital’s standard chromogenic assay.  
Results: A statistically significant correlation was found between the fluorogenic and the 
chromogenic anti-FXa assays for 10 patient samples, with a slope of 0.936, offset of 0.228 
and an R
2
 of 0.71 (p<0.002). 
Conclusions: In the study presented here, a fluorogenic anti-FXa assay was correlated with a 
standard laboratory chromogenic anti-FXa assay using samples from patients on LMWH 
therapy. Significant correlations between the values derived by the fluorogenic and 
chromogenic anti-FXa assays were found for the patient cohort tested in this study. 
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Introduction 
Low molecular weight heparins (LMWHs) are a group of anticoagulant drugs that are used in 
the treatment of venous thrombosis, cardiovascular disease, thrombotic and ischaemic stroke 
worldwide [1, 2]. A significant advantage of LMWHs over unfractionated heparin (UFH) is 
the fact that, monitoring in the large majority of patients is not essential. However, special 
patient cohorts do exist where monitoring becomes important, and so hospital laboratories 
must establish suitable methodologies for quantifying the effect of LMWHs [3]. LMWHs 
undergo renal clearance which can result in anticoagulant accumulation in patients suffering 
from kidney failure [4, 5]. In addition, dosing of LMWH according to body weight may 
overestimate the dose for morbidly obese patients, as the anticoagulants may concentrate in 
the vascular tissue and blood, due to the lower proportion of lean body mass as a percentage 
of total body weight [4, 6]. Moreover, LMWH monitoring is essential in elderly patients, as 
lean body mass percentage decreases with age, which can result in overestimation of LMWH 
dose and in general, bleeding risk also increases with age [4]. Challenges also arise with the 
prescription of anticoagulants during pregnancy. Changes in maternal weight during the 
progression of pregnancy, increased bleeding risks in the mother and foetus, and bleeding 
associated with childbirth all complicate LMWH dosing, reinforcing the need for drug 
monitoring [6].  
Some of the standard coagulation monitoring assays such as the activated partial 
thromboplastin time test (APTT) or the activated clotting time test (ACT) are not sufficiently 
discriminatory for monitoring LMWHs, suffer from inter-laboratory variability and are 
lacking in standardization [2, 7, 8]. LMWHs exert their anticoagulant effect via interaction 
with the pentasaccharide-binding domain on antithrombin (AT), which in turn enhances the 
inhibitory effect of AT on factor Xa (FXa) [9]. Due to this high anti-FXa activity of LMWH, 
anti-FXa assays are the standard monitoring methods for patients on LMWH therapy [5]. The 
   
 
most widely used central laboratory anti-FXa assays are based on chromogenic substrates 
[10]. Originally developed by Teien and co-workers in 1976, these assays have a very simple 
mode of operation whereby heparin-accelerated antithrombin inhibits exogenous FXa and the 
residual FXa activity is determined by amidolysis of the FXa selective chromogenic peptide 
substrate. The resultant photometric signal is inversely proportional to the anticoagulant 
concentration in the sample [11]. 
A potential advantage of anti-FXa assays is that they are not affected by many of the 
biological variables that interfere with clot-based endpoints, thus reducing assay variability 
[12]. Despite improvements in the chromogenic assay mechanism, poor correlative data 
between commercial anti-FXa chromogenic assays has been reported. This again highlights 
the need for proper standardization of newly developed assays to reduce inter-laboratory 
variation and increase confidence in the use of such assays for clinical application. 
One major limitation of laboratory-based chromogenic assays is their inability to measure 
colorimetrically in whole blood samples. Optical clarity is of utmost importance in 
conducting photometric measurements, rendering turbid media such as whole blood and 
platelet rich plasma (PRP) unsuitable for application to colorimetric assays [13]. Fluorogenic 
assays on the other hand, do allow for measurement in whole blood and PRP, as sample 
opacity is not imperative to the performance of the assay and the fluorescent signal is not 
hampered by fibrin formation or turbidity caused by platelets [14]. Hence assays using 
fluorescent labels offer significant advantages over assays using colorimetric determination, 
in addition to the greater sensitivity and specificity associated with fluorescence 
measurements [12, 15]. In this paper, we evaluated the suitability of a fluorogenic anti-FXa 
assay for monitoring LMWH therapy in patient samples using the standard laboratory 
chromogenic anti-FXa assay as the reference method. Based upon our findings we have 
   
 
identified a novel assay for monitoring LMWH therapy, that correlates significantly with the 
standard chromogenic assay for patients on LMWH therapy (R
2
 = 0.71, p<0.002). 
   
 
Materials and methods 
Reagents 
Water (molecular biology grade) and HEPES buffer (minimum 99.5% titration) were 
purchased from Sigma-Aldrich (Dublin, Ireland). Filtered HEPES buffer was prepared at a 
concentration of 10 mM (pH 7.4). A 100 mM filtered stock solution of CaCl2 from Fluka 
BioChemika (Buchs, Switzerland) was prepared from a 1 M CaCl2 solution.  
The fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-4-
methylcoumarin acetate (Pefafluor FXa) was purchased from Pentapharm (Basel, 
Switzerland). It was reconstituted in 1 ml of water having a final concentration of 10 mM, 
aliquoted and stored at -20°C. Dilutions from 10 mM stock solutions down to 10 µM were 
freshly prepared with water when needed. Subsequent dilutions were prepared in 10 mM 
HEPES. Tubes were covered with aluminum foil to protect from exposure to light. Purified 
human FXa (serine endopeptidase; code number: EC 3.4.21.6) was obtained from Hyphen 
BioMed (Neuville-Sur-Oise, France). Tinzaparin (Innohep®) was obtained from LEO 
Pharma (Ballerup, Denmark) and enoxaparin (Clexane®) was obtained from Sanofi-Aventis 
(Paris, France). Human pooled plasma was purchased from Helena Biosciences Europe (Tyne 
and Wear, UK). Lyophilised plasma was reconstituted in 1 ml of water and left to stabilize 
for at least 20 min at room temperature prior to use.  
Apparatus and software 
Fluorescence intensities were measured on an Infinite M200 microplate reader from Tecan 
Group Ltd. (Männedorf, Switzerland) equipped with a UV Xenon flashlamp. Flat, black-
bottom 96-well polystyrol FluorNunc™ microplates from Thermo Fisher Scientific 
(Roskilde, Denmark) were used.  
 
 
   
 
LMWH calibration curve 
Measurements were carried out in reconstituted citrated human pooled plasma spiked with 
pharmacologically relevant concentrations (0–1 U/ml) of two low molecular weight heparins; 
enoxaparin and tinzaparin. Each well contained 6.25 µl of 100 mM CaCl2, 43.75 µl of pooled 
plasma and 50 µl of 12 nM FXa. The reaction was started by adding 50 µl of 2.7 µM 
Pefafluor FXa fluorogenic substrate. These assay concentrations were optimized as 
previously outlined [12]. All the measurements were carried out in triplicate. Samples within 
wells were mixed with the aid of orbital shaking at 37°C for 30 s. Immediately after shaking, 
fluorescence measurements were recorded at 37°C for 60 min, with a 20 µs integration time.  
Fluorescence excitation was at 342 nm and emission was monitored at 440 nm, 
corresponding to the excitation/emission wavelengths of the 7-amino-4-methylcoumarin 
(AMC) fluorophore.  
Patient samples 
A cohort of 24 frozen plasma samples from patients on LMWH therapy were collected from 
the National Centre for Hereditary Coagulation Disorders (NCHCD) at St. James’s Hospital, 
Dublin, Ireland. The anti-FXa levels of all patient samples were determined in the NCHCD, a 
National External Quality Assessment Service (NEQAS) approved laboratory, using the 
approved HemosIL TEST™ HEPARIN anti-FXa chromogenic assay from Instrumentation 
Laboratory Company (Massachussetts, USA) for the determination of heparin in plasma, 
using the ACL 9000™ automated haemostasis testing system also from Instrumentation 
Laboratory Company. Ethical approval for the use of patient samples was granted by the 
ethics committee in St. James’s Hospital. 
Patient samples were thawed at 37ºC in a water bath for 5 min and inverted for 5 min before 
testing in the anti-FXa fluorogenic assay. The assay protocol was followed as previously 
   
 
described in Section 2.3 except that calibration plasma was replaced with patient plasma. All 
measurements were carried out in triplicate. 
Data and statistical analysis 
In all experiments, reaction progress curves were obtained and analyzed in SigmaPlot 8.0. 
The reaction rate (slope) was defined as the change in fluorescence divided by the change in 
time (i.e. dF/dt) and was measured as the linear portion of the fluorescence response profile. 
Statistical analysis was carried out using SPSS 17.0 software. For statistical analysis, raw 
data was transformed logarithmically and analyzed using one-way analysis of variance 
(ANOVA), with subsequent post-hoc analysis (Duncan, Tukey and Dunnett) if significance 
was observed. A result of p<0.05 was considered statistically significant.   
A single calibration curve of the rate of fluorescence formation versus LMWH concentration 
was generated by averaging the triplicate measurements for enoxaparin and tinzaparin at each 
concentration in the statistically sensitive range which was established as 0-0.8 U/ml 
(p<0.05).  The data for the calibration curve are presented as the mean ±SD (n=3). 
The best fit for the LMWH calibration curve was determined as the linear regression of the 
log transformation of the data. The reaction rates were calculated for all patient samples and 
inserted into the linear regression equation to determine the LMWH concentration for each 
patient sample. 
The LMWH concentrations determined by the fluorogenic anti-FXa assay were correlated 
with the LMWH concentration determined by the chromogenic anti-FXa assay in the 
NCHCD, St. James’s Hospital, Dublin. The NEQAS approved HemosIL TEST™ HEPARIN 
anti-FXa chromogenic assay reports linearity from 0-1.1 U/ml, with run-to-run and day-to-
day precision of <10%. 
   
 
Results 
The fluorogenic anti-FXa assay was performed in control plasma samples spiked with 
increasing concentrations of LMWHs. The dose-response profile was calculated using the 
initial linear portions of the fluorescence profiles for each LMWH concentration. Linear least 
squares regression curve fitting was performed on the resulting dose-response curve using log 
ordinates. Fig. 1 shows the linear regression calibration curve of the log transformation of the 
raw data reaction rates for calibration plasma spiked with LMWHs from 0 to 0.8 U/ml. The 
regression equation was y = -0.8095x + 2.1063 and the R
2
 value observed was 0.995. Least 
squares analysis was performed in order to determine the best curve fit for this set of data 
which returned low sum of squares (SS) values for the log linear fit, indicating small errors 
and best fit. 
To evaluate the fluorogenic anti-FXa assay, 24 plasma samples from patients on LMWH 
therapy were tested in the assay and the fluorescence profiles of a representative sample of 
the different profiles can be seen in Fig. 2. All patient samples differed in terms of their 
fluorescence profiles, which would be expected given the different dosages, time elapsed 
since dose administration and clearance rates of the individual patients. Some samples 
showed rapid increases in fluorescence indicating the presence of low residual drug dosages. 
Other samples failed to show an increase in fluorescence and the profiles remained flat for 
the duration of the assay which indicated a LMWH dose above the range of the assay.  
The LMWH concentration for these patient samples was also determined using the routine 
hospital chromogenic anti-FXa assay, so it was possible to correlate the fluorogenic anti-FXa 
assay with the standard chromogenic assay. The linear reaction rate for each patient was 
calculated from the fluorescence profiles. Patient samples that did not show an increase in 
fluorescence throughout the assay were excluded from the study as they were outside the 
therapeutic range. LMWH concentrations from 0 to 0.1 U/ml and greater than 1 U/ml, as 
   
 
determined by the chromogenic assay results, were not included in the correlative analysis, as 
they also fell outside the therapeutic range. These omissions resulted in a final patient sample 
cohort of 10.  Using the fluorescence rate slopes, the LMWH concentration was calculated 
using the log linear regression equation, y = -0.8095x + 2.1063. The concentrations were then 
correlated with the values reported by the hospital chromogenic assay. Fig. 3 shows the 
correlation between the LMWH concentrations derived from the fluorogenic anti-FXa assay 
and the chromogenic anti-FXa assay for 10 patient samples which had a slope of 0.936, offset 
of 0.228 and an R
2
 value of 0.71. 
Bland-Altman analysis was used to assess the level of agreement between the two methods to 
compare the new fluorogenic anti-FXa assay being established. Data were displayed by 
plotting difference vs. mean as can be seen in Fig. 4. The values for the fluorogenic assay 
were all less than zero, indicating that the results are consistently higher than the standard 
reference method. Bland-Altman analysis indicates that the 95% limits of agreement between 
the two methods ranged from -0.6 to 0.03 with all samples falling into this range. 
 
 
   
 
Discussion 
LMWHs have been highlighted as more convenient, safe, and effective anticoagulants when 
compared with UFH [16].  LMWHs have greater bioavailability and are easily absorbed after 
subcutaneous injection, they a have more predictable dose-response relationship and the 
lower molecular weight and shorter polysaccharide chain length of LMWHs, results in less 
non-specific binding to plasma proteins [17]. Despite the general consensus that monitoring 
for LMWH is unnecessary, patient populations including the elderly, children, pregnant 
women, patients with renal insufficiency and patients at extreme weights, do exist where 
dosing of anticoagulants becomes unpredictable [6].  
The typical method for monitoring LMWH is by means of the anti-FXa chromogenic assay, 
which is employed by some central laboratories. Certain drawbacks are associated with 
chromogenic assays such as lack of standardization and high cost [7]. Sample type is also an 
issue with these assays in that they can only be performed with platelet poor plasma (PPP) 
and preparation of PPP requires time-consuming pre-analytical procedures resulting in long 
turnaround times. Fluorescent detection is a suitable alternative to colorimetric measurement 
due to high sensitivity and specificity in addition to the broad range of fluorophores and 
labelling chemistries available for different coagulation proteins [15]. Furthermore, 
fluorescent detection allows for measurement in PPP in addition to platelet rich plasma (PRP) 
and whole blood [11, 12]. The aim of the present study was to compare a novel fluorogenic 
anti-FXa with the chromogenic anti-FXa assay used in the hospital setting using plasma 
samples from patients on LMWH therapy. 
In this study, a fluorogenic anti-FXa assay is presented that is suitable for measuring LMWH 
anticoagulants. The fluorogenic anti-FXa assay has a statistically sensitive range up to 0.8 
U/ml at intervals of 0.2 U/ml. Plasma samples from patients receiving LMWH therapy were 
   
 
tested in this assay and correlations were performed with the anti-FXa reference method 
using linear regression analysis.  
In total, 24 patient samples were tested and 10 samples were not included in the analysis as 
they failed to show a fluorescence increase due to high dose heparin therapy. All samples 
falling into the 0-0.1 U/ml range and above 1 U/ml, were also excluded from the analysis as 
they fall outside the therapeutic range. Analysis was performed using the log linear regression 
equation with a final sample number of ten patients. A significant correlation (R
2
 = 0.71) 
between LMWH concentrations derived from the fluorogenic anti-FXa assay and the 
chromogenic anti-FXa assay was established for patient samples (p<0.05). 
It has long been established that traditional clot-based assays do not return equivalent results 
for the same patient sample. Variation in reagents, coagulometers, and operators but also in 
the nature of the mode of assay operation, i.e. clot-based assays, all contribute to the lack of 
consistency between assay results [18, 19]. 
The Prothrombin Time (PT) is a clotting assay standardized using the International 
Normalised Ratio (INR) so as to overcome the problem of assay variability between 
laboratories. Despite this standardization, poor agreement among PT methods has been 
observed [20]. Variability in APTT reagent sensitivity for monitoring heparin has also been 
observed, resulting in a lack of correlation between assays for the same samples [18, 19]. 
A lack of correlation exists between heparin dose and standard clinical monitoring tests in 
children on UFH therapy [21]. However, the absence of a correlation may also relate to the 
fact that assays such as the APTT, have been developed based on adult coagulation systems 
which are quite different to those of children, in terms of clotting factor levels.  
Chromogenic assay comparisons have also resulted in differing results. Kovacs et al. 1999 
assessed whether three commercially available chromogenic methods on two different 
instruments gave equivalent results for patients on anticoagulant therapy. While the R
2
 values 
   
 
for the correlations were 0.97-0.99 for UFH and 0.97-0.98 for LMWH, the mean anti-FXa 
levels were statistically different when analyzed using one-way ANOVA and subsequent 
Bonferroni analysis. A mean difference of as high as 0.16 U/ml in heparin levels as deduced 
by anti-FXa analysis has also been published [22]. Such differences can be attributed to 
instrument and assay variability. Taking these results into consideration, the authors 
suggested that the therapeutic heparin range as determined by anti-FXa assays should be 
instrument and assay specific [22, 23].  
Anti-FXa assays vary according to the technique employed [24] as has been outlined by 
previous correlations between clot-based and chromogenic assays [21, 24]. The comparison 
of a thrombolytic assessment system heparin management test (TAS HMT) and the ACT 
with chromogenic anti-FXa levels for 10 patients on heparin therapy, returned statistically 
significant but marginal correlation coefficients, reported as R
2
 = 0.53 (p<0.002) and R
2
 = 
0.64 (p<0.001), respectively [25]. To overcome this variability the ideal solution would be 
the introduction of a global standard assay. 
In this study we present a novel fluorogenic anti-FXa assay which surpasses chromogenic 
assays in terms of sensitivity, specificity and most importantly in terms of the range of 
sample types that can be used in this assay. We report a statistically significant correlation 
between the fluorogenic and the chromogenic anti-FXa assays for ten patient samples as R
2
 = 
0.77 (p<0.002) for the log linear calibration, with all values falling within the 95% limits of 
agreement. The excellent correlation of both assays observed, indicates the potential of the 
fluorogenic assay for the laboratory monitoring of LMWH therapy in addition to its inherent 
advantages as previously described, over colorimetric-based measurement techniques. 
In summary, a recently developed fluorogenic anti-FXa assay was correlated with the 
standard laboratory chromogenic anti-FXa assay using samples from patients on LMWH 
   
 
therapy. Significant correlations between the values derived by the fluorogenic and 
chromogenic anti-FXa assays were found for the patient cohort tested in this study. 
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Figure legends 
Fig. 1: Calibration curve for the fluorogenic anti-Factor Xa assay performed according to 
linear least squares regression of the log transformation of the raw data, y = -0.8095x + 
2.1063, R
2
 = 0.995.  
Fig. 2: Fluorescence profiles of selected number of patient samples in the fluorogenic anti-
FXa assay. 
Fig. 3: Correlation of calculated concentrations of LMWH activity from the fluorogenic and 
chromogenic assays using the log linear regression fit, y = 0.936x + 0.228, R
2
 = 0.71. 
Fig. 4: Bland-Altman plot illustrating differences against averages for the standard 
chromogenic assay compared with the fluorogenic assay (y = -0.113x - 0.119, R
2
 = 0.036). 
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